Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Fuxius

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Liposomal formulations of anticancer drugs: selectivity and effectivenessUlrich Massing, Stefan Fuxius
Radiologie (Heidelberg, Germany)|June 26, 2025
[Malignant lymphoma]Stefan Delorme, Stefan Fuxius, Marius Mayerhöfer
Anti-Cancer Drugs|October 24, 2002
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancerStefan Fuxius, Klaus Mross, Kambiz Mansouri, et al.
Frontiers in Oncology|December 7, 2018
Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common TaxanesSaskia Spaich, Johanna Kinder, Svetlana Hetjens, et al.
Clinical Nuclear Medicine|August 15, 2021
Two Tumors, One Target: Preliminary Experience With 90Y-FAPI Therapy in a Patient With Metastasized Breast and Colorectal CancerHendrik Rathke, Stefan Fuxius, Frederik L Giesel, et al.
The Prostate|January 19, 2016
Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancerJost von Hardenberg, Maike Schwartz, Thorsten Werner, et al.
Anticancer Research|September 6, 2017
Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During DocetaxelJost VON Hardenberg, Maike Schwartz, Thorsten Werner, et al.
Urologia Internationalis|July 13, 2017
Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature ReviewJost von Hardenberg, Maike Schwartz, Thorsten Werner, et al.
Oncology Research and Treatment|October 5, 2018
Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate CancerJost von Hardenberg, Thomas S Worst, Niklas Westhoff, et al.
Oncology Research and Treatment|February 16, 2026
Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapiesRudolf Weide, Johannes Mohm, Michael Gärtner, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Liposomal formulations of anticancer drugs: selectivity and effectivenessUlrich Massing, Stefan Fuxius
Radiologie (Heidelberg, Germany)|June 26, 2025
[Malignant lymphoma]Stefan Delorme, Stefan Fuxius, Marius Mayerhöfer
Anti-Cancer Drugs|October 24, 2002
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancerStefan Fuxius, Klaus Mross, Kambiz Mansouri, et al.
Frontiers in Oncology|December 7, 2018
Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common TaxanesSaskia Spaich, Johanna Kinder, Svetlana Hetjens, et al.
Clinical Nuclear Medicine|August 15, 2021
Two Tumors, One Target: Preliminary Experience With 90Y-FAPI Therapy in a Patient With Metastasized Breast and Colorectal CancerHendrik Rathke, Stefan Fuxius, Frederik L Giesel, et al.
The Prostate|January 19, 2016
Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancerJost von Hardenberg, Maike Schwartz, Thorsten Werner, et al.
Anticancer Research|September 6, 2017
Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During DocetaxelJost VON Hardenberg, Maike Schwartz, Thorsten Werner, et al.
Urologia Internationalis|July 13, 2017
Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature ReviewJost von Hardenberg, Maike Schwartz, Thorsten Werner, et al.
Oncology Research and Treatment|October 5, 2018
Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate CancerJost von Hardenberg, Thomas S Worst, Niklas Westhoff, et al.
Oncology Research and Treatment|February 16, 2026
Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapiesRudolf Weide, Johannes Mohm, Michael Gärtner, et al.
Pageof 3